Advarra Acquires YourEncore
Advarra has announced the acquisition of YourEncore.
“We’re excited that YourEncore is becoming part of Advarra,” said Gadi Saarony, CEO of Advarra. Together, they will aim to progress a shared vision of accelerating the drug development lifecycle and the delivery of therapies to patients.
Advarra’s consulting services currently assist biopharmaceutical companies, device manufacturers, academic medical centers, health systems, and institutions in nearly 60 countries. “The addition of YourEncore is a huge step forward for Advarra’s consulting services business, building on and broadening our existing team and solutions across the clinical research spectrum,” said Scott Uebele, President and Chief Research Services Officer of Advarra.
For more information, click here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
